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Abstract
Background: Scintigraphic studies have been performed to assess the release, both in vitro and in
vivo, of radiotracers from tablet formulations. Four different tracers with differing physicochemical
characteristics have been evaluated to assess their suitability as models for drug delivery.
Methods: In-vitro disintegration and dissolution studies have been performed at pH 1, 4 and 7. In-
vivo studies have been performed by scintigraphic imaging in healthy volunteers. Two hydrophilic
tracers, (99mTc-DTPA) and (99mTc-MDP), and two lipophilic tracers, (99mTc-ECD) and (99mTc-MIBI),
were used as drug models.
Results: Dissolution and disintegration profiles, differed depending on the drug model chosen. In
vitro dissolution velocity constants indicated a probable retention of the radiotracer in the
formulation. In vivo disintegration velocity constants showed important variability for each
radiopharmaceutical. Pearson statistical test showed no correlation between in vitro drug release,
and in vivo behaviour, for 99mTc-DTPA, 99mTc-ECD and 99mTc-MIBI. High correlation coefficients
were found for 99mTc-MDP not only for in vitro dissolution and disintegration studies but also for in
vivo scintigraphic studies.
Conclusion: Scintigraphic studies have made a significant contribution to the development of drug
delivery systems. It is essential, however, to choose the appropriate radiotracers as models of drug
behaviour. This study has demonstrated significant differences in release patterns, depending on the
model chosen. It is likely that each formulation would require the development of a specific model,
rather than being able to use a generic drug model on the basis of its physicochemical
characteristics.
Background
Development of new drug formulations requires the per-
formance of extensive studies, both in the laboratory, and
in vivo, in animals and in volunteers. In vitro studies can be
very expensive but costs are even higher when in vivo
stages are reached. Methodology that can generate rele-
vant information but shorten the preformulation phases
means important savings in economic, human and time
terms [1-9]. Gamma scintigraphy provides rapid, comple-
mentary information that often cannot be obtained by
other methodologies. It has been successfully used during
development stages of feasibility studies and in
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information obtained by scintigraphy gives support dur-
ing investigation and development, and also comple-
ments the development of registration dossiers and
marketing publicity. The incorporation of a radiopharma-
ceutical into a drug formulation allows determination of
the biodistribution kinetics and the release sites [10-14].
It is very important to choose the proper radionuclide,
often 99mTc (technetium), as this has optimal characteris-
tics of half-life and energy, allowing images to obtain with
high efficiency and low doses [15,16].
Many studies to validate the methodology mentioned
above have already been undertaken [17,18], but, in gen-
eral within these studies, radiopharmaceuticals are only
rarely used as drug surrogates. Radiopharmaceuticals were
primarily developed for diagnostic purposes in nuclear
medicine, most of them being intended for intravenous
administration. In order to optimise the usage of radiop-
harmaceuticals in the development of pharmaceutical
drug-delivery systems, the behaviour of these tracers fol-
lowing administration by other routes must be validated.
Stability and in vitro studies of different radiopharmaceu-
ticals have been previously reported by our group [17],
with the aim of creating a database of radiotracers or
model drugs with known physicochemical properties to
be used as in pharmaceutical dosage development, partic-
ularly of tablet formulations.
Provided that the tablet formulation can be radiolabelled
with a suitable gamma emitter without altering its charac-
teristics, imaging with a gamma camera can be used to
monitor in vivo transit and dispersion of the tablet, and
give some indication of deposition and absorption of the
drug. The aim of this work is to assess in vivo and in vitro
behaviour of a tablet formulation using scintigraphic stud-
ies, to examine the way in which radiopharmaceuticals
model the release of drugs, using four different tracers
with different physicochemical characteristics. Based on
this assessment, the correlation between in-vitro and in-
vivo behaviour could be investigated.
The characterised radiopharmaceuticals were 99mTc-dieth-
ylenetriamine-pentaacetic acid (99mTc-DTPA), 99mTc-ethyl
cysteinate dimer (99mTc-ECD), 99mTc-methylene diphos-
phonate (99mTc-MDP) and 99mTc-sestamibi (99mTc-MIBI)
[17]. They were incorporated into the tablets during wet
granulation. Disintegration profiles were assessed in vitro
in dissolution vessels and in vivo by scintigraphic imaging
in healthy volunteers. In vitro dissolution studies were per-
formed for tablets containing the above-mentioned
radiotracers
Methods
Radiopharmaceuticals labelling and control
The radiopharmaceuticals 99mTc-DTPA, 99mTc-ECD,
99mTc-MDP and 99mTc-MIBI were obtained by labelling
commercial kits with 99mTcO4- from a 99Mo /99mTc gener-
ator (Technonuclear). Radiochemical purity testing of the
99mTc-DTPA complex was performed by chromatographic
analysis on Whatman N° 1 paper with propanone and
sodium chloride solution (0.9%) as developing solvents.
99mTc-ECD radiochemical purity was studied by chroma-
tography on Whatman N°1 paper with a methanol/water
(85/15) solvent and by HPLC (Shimadzu LC-10 AS) using
a Partisphere C18 (Whatman) column as the stationary
phase. The mobile phases were phosphate buffer 0.0125
M pH 2.5 (A), and ethanol 100% (B). Solvent program
was, at time = 0 min, 100 % A, and at time = 10 min, 70%
A, 30% B. The flow rate was set at 2 mL min-1.
The radiochemical purity of 99mTc-MDP was determined
by chromatography on Whatman N°1 paper using pro-
panone and sodium chloride 0.9 % as developing
solvents.
The 99mTc-MIBI complex was assessed by HPLC (Shi-
madzu LC-10 AS) using a Partisphere C18 (Whatman)
column 12.5 cm as stationary phase. The mobile phases
were methanol (A), and ammonium sulphate 0.05 M (B).
Solvents program was at time = 0 min, 20 % A, and at time
= 5 min, 95% A. The flow rate was set at 2 mL min-1.
Tablet preparation
Tablets were prepared by wet granulation using lactose
and starch as diluents, PVP K30 (ISP Corp) as granulating
agent, Ac-Di-Sol (FMC Biopolymer) as disintigrant and
magnesium stearate as lubricant. The exipients were
passed through a No. 16 sieve (16 meshes per centimetre)
and mixed by a geometric method. After compression,
tablets were assessed for weight (target weight 400 mg)
and radioactivity content (target activity 18.5 MBq). Activ-
ity was measured in an ionisation chamber dose calibrator
(Capintec CRC 25).
Tracer stability was verified as in a previous communica-
tion [18] both during tablet preparation and in dissolu-
tion and disintegration studies.
In vitro studies
Dissolution tests were carried out in a Vankel USP Type II
apparatus, 900 mL of dissolution medium was used at
three different pH values comprising pH 1 (0.1 M hydro-
chloric acid), pH4 (0.016 M acetic acid/sodium acetate)
and pH 7 (water). Temperature was maintained at 37°C,
and a rotation speed of 50 r.p.m. used. Samples of 2 mL
were withdrawn through cellulose acetate membranePage 2 of 8
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assessed for radioactivity in a solid scintillation counter
(Ortec-Maestro MCB1). Corrections were applied for vol-
ume, decay and counting efficiency. Curves of log % non-
dissolved vs. time were plotted.
Disintegration profiles were recorded concurrently with
the dissolution procedure by placing the vessels in front of
a circular field of view gamma camera (Dyna (Pyker 4/15)
equipped with a low energy, high resolution collimator,
operating with a 20% window centred on 140 Kev. Serial
images were recorded at 1 frame/min with a matrix of 128
× 128 without acquisition zoom. Three regions of interest
were delineated, one on the tablet, one on the dissolution
medium and the third on the external field to determine
the background [19]. Net activity was calculated by sub-
tracting mean background pixel counts from each pixel in
the selected region of interest. No attenuation correction
was necessary.
In vivo studies
Studies were performed in four healthy volunteers (2 men
and 2 women) mean weight 60 Kg, mean age 38 years.
They were non smokers and were not receiving any medi-
cation. Written informed consent was obtained from all
subjects. They were not allowed to consume alcohol dur-
ing the study period or in the preceding 24 hours. The pro-
tocol was in accordance with the Declaration of Helsinki
guidelines for ethics in research and with resolutions XXIX
and XXXV of the World Medical Assembly.
Volunteers fasted for 6 hours prior to the study. Tablets
were administered with 200 mL of still mineral water. Vol-
unteers stood erect during the acquisition process in front
of the detector. Urine samples were collected at 30 and
120 minutes post ingestion [22,23].
Serial images were recorded during the 30 minute period
after administration at 2 frames / min using a rectangular
field view gamma camera (Sophy). Later static images
were recorded 2 hours after tablet intake.
Three regions of interest were delineated, one on the
stomach, one on the intestines and a third on a region
outside the body perimeter to determine the background.
Net activity was quantified by subtracting mean back-
ground pixel counts from each pixel in the selected region
of interest. Gamma ray attenuation was quantified by cal-
culating the geometric means of count rates in paired
anterior and posterior planar views.
Scintigraphic studies enabled the determination of tablet
transit characteristics within the gastrointestinal tract spe-
cifically in the stomach. Curves of Log % non-disinte-
grated vs. time were plotted [24,25].
Data processing
Disintegration velocity constant of the tablets was kd,
which corresponded to the slope of the linear regression
in first order kinetics [26]:
log [1- Qt/Q∞] = kdt / 2.303
Where
Qt the amount of activity of the tracer disintegrated at time
t present in the region of interest.
Q∞ the maximum amount of activity measured in the
region of interest.
Disintegration velocity constants in the stomach and the
constant of appearance in small intestine were deter-
mined in a similar way, considering Qt the amount of
activity of the tracer disintegrated at time t present in the
region of interest and Q∞ the total amount of activity of
the region at the end of the study [27].
Results and Discussion
Radiotracers were incorporated during the wet granula-
tion process of tablet preparation and appropriate con-
trols of quality were applied as previously described [17].
All the radiopharmaceuticals were produced with radio-
Table 1: In vitro dissolution and disintegration constants (p 0.05)
Radiopharmaceutical Dissolution velocity Constant (min-1) (n = 6) Disintegration velocity Constant (min-1) (n = 6)
99mTc-MIBI (0.05 ± 0.02) all pH range (0.04 ± 0.01) all pH range
99mTc-ECD (0.040 ± 0.005) all pH range (0.05 ± 0.01) (pH 1)
(0.09 ± 0.01) (pH4 and 7)
99mTc-MDP (0.020 ± 0.005) all pH range (0.20 ± 0.04) (pH 1 and 7)
(0.040 ± 0.005) (pH 4)
99mTc-DTPA (0.06 ± 0.01) (pH1and 7)
(0.11 ± 0.02) (pH 4)
0.011 ± 0.002 (pH1and 7)
0.080 ± 0.006 (pH 4)Page 3 of 8
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manufacturers' specifications.
Disintegration velocity constants in the gastrointestinal
tract were determined by in vivo scintigraphic studies, spe-
cifically in stomach and small intestine for the different
radiopharmaceuticals evaluated as tracers.
In vitro results
99mTc-MIBI
Dissolution velocity constants for tablets containing this
lipophilic tracer showed no significant variation across
the whole pH range studied and the values were very sim-
ilar to disintegration velocity constants determined under
the same conditions (Table 1).
The Pearson statistical test was used to quantify correla-
tion within both series of data. Pearson's correlation coef-
ficient r is always between -1 and 1 indicating that the
points are near a negative or a positive slope respectively.
The closer the r value is to -1 or 1 the higher the correla-
tion of the series is. [27]
Dissolution and disintegration velocity constants (r val-
ues) were compared using this test. Correlation coeffi-
cients are shown in Table 3.
They were not so high indicating a probable retention of
the radiotracer in the formulation.
99mTc-ECD
This lipophilic radiopharmaceutical demonstrated identi-
cal dissolution velocity constants across the whole pH
range studied, while disintegration velocity constants
increased with pH (Table 1).
Pearson correlation coefficients are shown in Table 3. A
high correlation was found.
99mTc-MDP
In vitro dissolution velocity constants did not show signif-
icant variation across the whole pH range while in vitro
disintegration velocity constants increased with pH (Table
1). In vitro correlation coefficients were high at all pH val-
ues. (Table 3)
99mTc-DTPA
In vitro dissolution and disintegration data showed simi-
lar patterns but the values were different (Table 1). In this
case at pH 1 and 7 both disintegration and dissolution
velocity constants were lower than those at pH 4. The pro-
files were similar in both series of data and Pearson corre-
lation was very high at all pH ranges studied. (Table 3)
In vivo results
99mTc- MIBI
No significant variability within volunteers was observed
in stomach disintegration velocity constants. Small intes-
tine appearance constant showed similar behaviour but
different values and did not represent significant differ-
ences within volunteers (Table 2). Two hours after admin-
istration there was no significant uptake in any organ
except urinary bladder (Figure 1). Pearson Test was used
to compare in vitro – in vivo disintegration velocity con-
stants (Table 4) assuming pH 1 for stomach and pH 4 for
small intestine no correlation was found. When Pearson
test was used for in vivo disintegration velocity constants
and in vitro dissolution ones, (Table 5) correlation coeffi-
cient was again low for stomach and a bit higher for small
intestine, but in neither case was correlation considered to
be established.
Table 2: In vivo gastric transit constants (p 0.05)
Radio pharmaceutical Stomach disintegration velocity Constant (min-
1) (n = 4)
Small intestine appearance Constant (min-1) (n 
= 4)
9mTc-MIBI (0.016 ± 0.006) (0.13 ± 0.02)
99mTc-ECD From (0.7 ± 0.1) to (0.010 ± 0.002) (0.02 ± 0.01)
99mTc-MDP (0.007 ± 0.002) (0.037 ± 0.006)
99mTc-DTPA From (0.13 ± 0.03) to (0.07 ± 0.01) From (0.004 ± 0.001) to (0.08 ± 0.01)
Table 3: In vitro dissolution – disintegration Pearson correlation 
coefficient
pH 99m Tc MIBI 99m Tc ECD 99m Tc MDP 99m Tc DTPA
1 0.75 0.99 0.68 0.99
4 0.77 0.78 0.90 0.99
7 0.50 0.94 0.68 0.99Page 4 of 8
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In this particular case there was a substantial inter subject
variability with coefficient variations during the 30-
minute study period ranging from 14 to 95 % (Table 2).
Small intestine appearance velocity constants were more
homogeneous and late images 2 hours after administra-
tion showed liver uptake (Figure 2).
Correlation coefficient was not significant when in vitro
disintegration – in vivo appearance velocity constants were
compared (Table 4).
When Pearson correlation was quantified between in vivo
disintegration velocity constants and in vitro dissolution
ones (Table 5) as indicated for 99mTc-MIBI, there was no
correlation at pH 1 (stomach) and it was low at pH 4
(small intestine).
99m Tc- MDP
No significant variations within volunteers were observed
in stomach disintegration velocity constants. Small intes-
tine appearance constant showed similar behaviour but
different values and did not represent significant differ-
99mTc-MIBI placebo tablet scintigraphic image 2 hours after drug intake for one volunteerFigure 1
99mTc-MIBI placebo tablet scintigraphic image 2 hours after 
drug intake for one volunteer.
Table 4: In vitro-In vivo disintegration velocity constants Pearson 
correlation coefficient.
pH 99m Tc MIBI 99m Tc ECD 99m Tc MDP 99m Tc DTPA
1 0.29 0.44 0.29 0.8
4 0.21 0.29 0.08 0.12
Table 5: In vitro dissolution – in vivo disintegration Pearson 
correlation coefficient
pH 99m Tc MIBI 99m Tc ECD 99m Tc MDP 99m Tc DTPA
1 0.13 0.08 0.68 0.07
4 0.51 0.69 0.59 0.12
Scintigraphic image 2 hours after drug intake for one volun-teer 99mTc-ECD placeb  tabletsFigure 2
Scintigraphic image 2 hours after drug intake for one volun-
teer 99mTc-ECD placebo tablets.Page 5 of 8
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istration there was no significant uptake in any organ
except urinary bladder (Figure 3). Pearson Test was used
to compare in vitro – in vivo disintegration velocity con-
stants (Table 4). In this case correlation was negligible.
When Pearson Test was used for in vivo disintegration
velocity constants and in vitro dissolution ones, (Table 5)
correlation coefficients had the highest values found in
this study.
99m Tc- DTPA
Significant variations within volunteers were observed in
stomach disintegration velocity constants and small
intestine appearance constants (Table 2). Two hours after
administration there was no significant uptake in any
organ except urinary bladder (Figure 4). Pearson Test was
used to compare in vitro – in vivo disintegration velocity
constants (Table 4).
In this case correlation was negligible for pH 4 and higher
for pH 1. When Pearson Test was used for in vivo disinte-
gration velocity constants and in vitro dissolution ones,
(Table 5) correlation was negligible for the entire gastroin-
testinal tract.
A good correlation was found between in vitro disintegra-
tion and dissolution velocity constants of tablets contain-
ing each of the radiopharmaceuticals used as radiotracer.
As scintigraphic studies give information of a physical
process, tablets containing the same components, but dif-
ferent tracers, might be expected to have a similar
behavior in all cases. As tracers are present in low concen-
trations (lower than 10-9 M), it is unlikely that they are
responsible for the observed differences in the disintegra-
tion constants. It is possible that the tracers are bound to
different components within the tablet, which disperse at
different rates, which would be a likely explanation.
Although the dissolution profiles might be expected to
differ depending on the model drug used, the same would
not be expected of the disintegration profile. This suggests
that the measured disintegration profile can depend on
the model chosen.
Scintigraphic image 2 hours after drug intake for one 99mTc-MDP pl cebo tabl ts in one volunteerFigure 3
Scintigraphic image 2 hours after drug intake for one 99mTc-
MDP placebo tablets in one volunteer. Scintigraphic image 2 hours after drug intake for one volun-teer 99mTc-DTPA placebo tabl tsFigure 4
Scintigraphic image 2 hours after drug intake for one volun-
teer 99mTc-DTPA placebo tablets.Page 6 of 8
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in the gastrointestinal tract. This is not a desirable charac-
teristic and makes it an unsuitable tracer for this type of
study. It was probably the main factor giving rise to the
greater inter individual variability disintegration velocity
constants observed when in vivo studies were performed
for 99mTc-ECD formulations. This fact was not observed
with the other radiotracers under the same conditions of
study.
Despite the physicochemical differences between 99mTc-
MIBI and 99mTc-DTPA, both tracers presented very low
correlation coefficients when in vitro dissolution – in vivo
disintegration velocity constants were compared through-
out the whole gastrointestinal tract (Table 3).
Only 99m Tc-MDP showed high correlation coefficients
both in vitro between dissolution and disintegration, and
between in vitro dissolution and in vivo disintegration.
Conclusion
Even though 99mTc-ECD, 99mTc-MIBI and 99mTc-DTPA
showed high in vitro correlation between dissolution and
disintegration, statistical tests revealed that none of them
was an adequate predictor of in vivo performance for this
particular tablet formulation, for any region of the gas-
trointestinal tract.
The hydrophilic radiotracer 99mTc-MDP was the only radi-
opharmaceutical suitable as a drug model for this particu-
lar tablet formulation in the prediction of its in vivo
behavior.
The method is an interesting tool especially at early stages
of pharmaceutical formulation development when differ-
ent formulations are being chosen, but may not have ade-
quate sensitivity to discriminate between formulation
variables.
Careful choice of drug model, together with substantial in
vitro validation is essential in order to reduce in vivo stud-
ies and make significant savings of human and financial
resources.
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